Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease

Efficacy of Intravenous Immunoglobulin in Management of RH and ABO Incompatibility Disease of Newborn and Its Effect in Decrease Duration of Hospital Stay and Need for Exchange Transfusion


Lead Sponsor: Assiut University

Source Assiut University
Brief Summary

hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born

Detailed Description

Hemolytic disease of the newborn (HDN) due to red cell alloimmunisation is an important cause of hyperbilirubinemia with significant morbidity in the neonatal period . Hemolytic disease of the newborn has unfortunately continued to contribute to perinatal and neonatal morbidity and mortality in developing countries . The degree to which the fetus is affected correlated with the amount of maternal antibody that cross the placenta .

Hemolysis from ABO incompatibility is one of the most common cause of isoimmune hemolytic disease during neonatal period. Infants with blood group type A or B , carried by blood group type O mother, will have a positive antibody because of maternal anti-A or anti-B transfer in to the fetal circulation. Ten percent of these infants will present with hemolytic disease . Most of the infant presents with unconjugated hyperbilirubinemia in the first 24 h of life and it is rarely a cause in patients who are discharged from nursery and readmit with severe hyperbilirubinemia.

Rh incompatibility can occur when an Rh-negative pregnant mother is exposed to Rh-positive fetal red blood cells secondary to fetomaternal hemorrhage during the course of pregnancy from spontaneous or induced abortion , trauma, invasive obstetric procedures, or normal delivery. As a consequence, blood from the fetal circulation, and, after a significant exposure, sensitization occurs leading to maternal antibody production against the foreign Rh antigen. Once produced, maternal Rh immunoglobulin G (IgG) antibodies may cross freely from the placenta to the fetal circulation, where they form antigen-antibody complexes with Rh- positive fetal erythrocytes and eventually are destroyed, resulting in a fetal alloimmune-induced hemolytic anemia and Jaundice.

Traditional neonatal treatment of HDN consists of intensive phototherapy and exchange transfusion (ET). However, ET is a high-risk invasive procedure associated with a significant rate of adverse effects .Although the mortality rate associated with ET is currently reported to be less than 0.3% in term infants , the morbidity rates can reach 74% and includes catheter-related complications, sepsis, thrombocytopenia and hypocalcemia

Intravenous Immunoglobulin G (IVIG) therapy has been widely used for a variety of indications in newborn period such as alloimmune neonatal thrombocytopenia and an adjunctive treatment of neonatal infections. American Academy of Pediatrics, recommends high dose IVIG (0.5_1 g/kg) as an additional treatment of Rh and ABO hemolytic disease and its use however there is no consensus on its routine use in ABO hemolytic disease yet .

IVIG "contains a spectrum of antibodies capable of interacting with and altering the activity of cells of the immune system as well as antibodies capable of reacting with cells such as erythrocytes". When hemolytic disease occurs, maternal antibodies present in the infant's blood attach to the antigen receptors on the infant's red blood cells. Specifically, the maternal antibody attaches its Fc region, the lower portion of the antigen, to specific immune system cells , such as machrophages, stimulating the destruction of the antigen-antibody complex and the red blood cell. It has been proposed that IVIG blocks the Fc receptor and therefore blocks the binding of the antibody to the antigen. With this blockade, hemolysis no longer occurs.

Neonatal treatment with intravenous immunoglobulin (IVIG) has been suggested as an altenative therapy to ET for isoimmune hemolytic jaundice to reduce the need for exchange transfusion and duration of phototherapy and hospitalization in isoimmune hemolytic disease of the newborn.

Overall Status Unknown status
Start Date July 1, 2017
Completion Date December 31, 2018
Primary Completion Date December 31, 2018
Phase Early Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
To measure duration of phototherapy Two days
Secondary Outcome
Measure Time Frame
duration of hospital stay Four days
Enrollment 30

Intervention Type: Drug

Intervention Name: intravenous immunoglobulin

Description: giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm

Other Name: gammaglobulin



Inclusion Criteria:

- 1)Gestational age more than or equal 37 weeks and postnatal age from 48hr-72hr.

2)Anemia with Reticulocytic count 10% 3)Serum total bilirubin around 18mg/dl .

Exclusion Criteria:

- 1)perinatal asphyxia. 2)Congenital malformation. 3)Severe respiratory distress. 4)Sepsis during hospital stay. 5)Metabolic problems . 6)Gestational age less than 37 weeks

Gender: All

Minimum Age: N/A

Maximum Age: 30 Days

Healthy Volunteers: No

Verification Date

June 2017

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Assiut University

Investigator Full Name: Reem ahmed

Investigator Title: Doctor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Intervention group

Type: Other

Description: Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group

Label: Control group

Type: Other

Description: Control group will recieve phototherapy only

Acronym IVIG
Patient Data Undecided
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Intervention Model Description: intervention group will recieve intravenous immunoglobulin and phototherapy and control group that will receive phototherapy only

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov